Glucobay

ApprovedSmall molecule

Bayer

Glucobay is one of 64 small molecule programs targeting Hypoglycemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoglycemiaActive, not recruiting

Type 2 DiabetesActive, not recruiting

HypoglycemiaApproved

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Glucobay

Bayer

Approved

1 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

Aurlumyn

BBTG International Inc.

Preclinical

1 4

Forxiga

AstraZeneca

Preclinical

3 5

Lovaza

AstraZeneca

Preclinical

1 6

Sulfonylureas

Eli Lilly

Preclinical

1 7

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

1 8

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 9

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

1 10

Insulins

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients

Completed· Bayer logo

Bayer··NCT01219582·9,364 enrolled

Drug1 trial

Special Drug Use Investigation of Glucobay OD

Completed· Bayer logo

Bayer··NCT01685502·2,289 enrolled

Metformin1 trial

Bioequivalence Study for Acarbose/Metformin FDC

Completed· Bayer logo

Bayer·Phase 1·NCT04065581·24 enrolled

Type 2 Diabetes1 trial

Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT00568074·131 enrolled

Treatment1 trial

Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting

Completed· Bayer logo

Bayer··NCT01333774·423 enrolled

1 more indication

Hypoglycemia1 trial

Treatment of Hypoglycemia Following Gastric Bypass Surgery

Completed·ZZealand University Hospital·Phase 4·NCT02527993·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Glucobay. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucobay compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucobay. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bayer

Glucobay

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety1 trial

Drug1 trial

Metformin1 trial

Type 2 Diabetes1 trial

Treatment1 trial

Hypoglycemia1 trial

References

Drug Info

Quick Facts

Related News